Relief Therapeutics receives FDA rare paediatric disease designation for RLF-TD011

22 May 2025 - Relief Therapeutics today announced that the US FDA has granted rare paediatric disease designation to RLF-TD011 ...

Read more →

FDA approves Genentech’s Susvimo for diabetic retinopathy

22 May 2025 - Genentech announced today that the US FDA has approved Susvimo (ranibizumab injection) 100 mg/mL for the treatment ...

Read more →

Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease

22 May 2025 - Approval based on the positive MATINEE and METREX Phase 3 trials. ...

Read more →

Belite Bio announces FDA granting of breakthrough therapy designation for tinlarebant for the treatment of Stargardt disease

21 May 2025 - Belite Bio today announced that the US FDA has granted breakthrough therapy designation for tinlarebant for ...

Read more →

FDA takes steps to enhance state importation programs to help lower prescription drug prices

21 May 2025 - The US FDA is continuing to take steps to help state importation programs provide safe, effective and ...

Read more →

Moderna provides update on BLA submission for combination vaccine against influenza and COVID-19

21 May 2025 -  Moderna today announced that in consultation with the US FDA, the Company has voluntarily withdrawn the ...

Read more →

US FDA grants approval for Jivi anti-hemophilic factor (recombinant), PEGylated-aucl in paediatric patients 7 to under 12 years of age with haemophilia A

19 May 2025 - Bayer announced that the US FDA has approved Jivi, a recombinant DNA-derived, extended half-life factor VIII ...

Read more →

ICER to assess treatment for smoking cessation

20 May 2025 - Report will be subject of Midwest CEPAC meeting in January 2026; draft scoping document open to ...

Read more →

US FDA approves BLA for Novavax's COVID-19 vaccine

19 May 2025 - Nuvaxovid is the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the US. ...

Read more →

Zai Lab receives US FDA fast track designation for ZL-1310, a DLL3 targeted antibody drug conjugate, for treatment of extensive stage small cell lung cancer

19 May 2025 - The Company is on track to initiate a pivotal study for ZL-1310 in small cell lung ...

Read more →

ICER publishes protocol for first annual launch price and access report

19 May 2025 - Report to be issued in October 2025. ...

Read more →

FDA clears first blood test used in diagnosing Alzheimer’s disease

16 May 2025 - New test provides less invasive option, reduces reliance on PET scans and increases diagnosis accessibility. ...

Read more →

PharmaTher announces FDA extends review period for ketamine; new approval goal date 9 August 2025

16 May 2025 -  PharmaTher today announced the US FDA has extended the approval goal date for the review of ...

Read more →

Amneal receives US FDA approval for Brekiya (dihydroergotamine mesylate) injection for the acute treatment of migraine and cluster headaches in adults

15 May 2025 - Product will be available for appropriate patients in the second half of 2025 ...

Read more →

ICER publishes final evidence report on treatment for retinitis pigmentosa

15 May 2025 - Independent appraisal committee voted that current evidence is adequate to demonstrate a net health benefit of ...

Read more →